Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00531479 · ClinicalTrials.gov registry record · Phase 3
Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 459
- Enrollment target
NCT00531479: Completed Phase 3 study, sponsored by Pfizer.
NCT00531479 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 459 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (41% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00531479, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 459 participants
- Enrollment target
Study Summary
This study compares the effectiveness and safety of the combination of anidulafungin and voriconazole compared to that of voriconazole alone (which is generally considered the standard of care) for the treatment of Invasive Aspergillosis.
Primary Outcome
Number of deaths measured 6 weeks after start of treatment. Time to death defined as date of death minus first treatment date + 1.
Interventions
- DRUG voriconazole
- DRUG anidulafungin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 459 participants |
| Start Date | 2008-07 |
| Est. Completion | 2011-05 |
| Phase | Phase 3 |
What the finished NCT00531479 record still lists
NCT00531479 is an interventional study that assigns participants to a tested intervention. The registered 459 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (41% lower).
The record links to 0 conditions, and to 2 interventions - of which voriconazole is the first listed.
NCT00531479 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00531479 about?
NCT00531479 is a clinical study titled "Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis". This study compares the effectiveness and safety of the combination of anidulafungin and voriconazole compared to that of voriconazole alone (which is generally considered the standard of care) for the treatment of Invasive Aspergillosis.
What is the current status of trial NCT00531479?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 459 participants. The study started on 2008-07. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00531479?
The interventions under investigation include: voriconazole (DRUG), anidulafungin (DRUG).
Who is sponsoring clinical trial NCT00531479?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00531479's enrollment target sits among peer trials
459 827th of 2000 higher than 1,174 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04452825 · 459 participants · NA
A New Psychotherapy Intervention for Older Cancer Patients
- NCT02977780 · 460 participants · Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
- NCT03427736 · 460 participants
Anesthetics and Analgesics in Children
- NCT03819933 · 460 participants · NA
Optimizing Family Counseling for Anticipated Extremely Preterm Delivery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia